<DOC>
	<DOCNO>NCT00484419</DOCNO>
	<brief_summary>A 16 week open-label study subject receive background metformin monotherapy . 150 subject randomize 1:1:1 receive 1 follow : open-label colesevelam HCl , open label rosiglitazone , open-label sitagliptin .</brief_summary>
	<brief_title>Effects Colesevelam HCl , Rosiglitazone , Sitagliptin Control Blood Glucose Lipids Type 2 Diabetes Patients Whose Blood Glucose Is n't Completely Controlled With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>HbA1C 7.0 % 10.0 % metformin monotherapy ; may withdraw ( nonmetformin ) drug HbA1C 6.5 % 9.5 % screening . Subjects currently treat thiazolidinedione exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Colesevelam HCl ,</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>metformin</keyword>
</DOC>